Genomic Scores and Prostate Cancer

A recent Cleveland Clinic study revealed for the first time that the molecular features of a low-grade tumor as measured by genomic testing, rather than the amount of tumor present on biopsy, can identify which cancers should be treated and which are safe to watch.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy